The occasional use of over-the-counter (OTC) epinephrine inhalers appears to be safe and effective when used according to labeled instruction by individuals with mild, intermittent asthma. However, gross misuse of these products can cause severe adverse reactions, including death. Limited survey data suggest that approximately 20% of individuals using OTC epinephrine inhalers have mild-to-moderate persistent asthma. According to recent consensus guidelines, these individuals should be under a physician's care and receiving corticosteroid therapy. If these products continue to be marketed, labeling should be strengthened to better educate users about appropriate and inappropriate use of OTC epinephrine inhalers intended for patients with mild, intermittent asthma.
W
hile occasional use of over-the-counter (OTC) epinephrine inhalers appears to be safe and effective when used according to labeled instruction by individuals with mild, intermittent disease, gross misuse or abuse of these products can cause severe adverse reactions, including death. This report evaluates the available evidence on the safety (including product labeling) and efficacy of OTC epinephrine inhalant devices intended for the treatment of mild asthma.
Materials and Methods
Published studies from the years 1966 to 1998 were identified through a MEDLINE search of English-language articles, using the key words epinephrine, adrenergic beta agonists, asthma, administration, inhalation, and drugs, nonprescription. A total of 16 articles were retrieved. Further information was obtained from a search of the file, F-D-C Reports, in the Lexis-Nexis database using the key words epinephrine, over-the-counter, and inhaler, yielding 12 reports; and from the final monograph published by the US Food and Drug Administration (FDA) for OTC bronchodilator drug products.
History and Status of OTC Epinephrine Inhalers
OTC epinephrine inhalers were first marketed in the United States in the 1960s. In 1976, the FDA published an advance notice of proposed rule making to establish a monograph for OTC cold, cough, allergy, bronchodilator, and antiasthmatic drug products, in conjunction with recommendations offered by the Advisory Review Panel responsible for evaluating data on the active ingredients in this drug class.
The tentative final monograph for OTC bronchodilator products was published in 1982, 1 in which the FDA concluded the following:
Epinephrine, epinephrine bitartrate, and epinephrine hydrochloride (racemic; since renamed racepinephrine hydrochloride) in pressurized metered-dose inhalation aerosol dosage forms can be generally recognized as safe and effective for OTC use at a dosage for adults and children 4 years of age and older of 1 to 2 inhalations of a metered-dose equivalent to 0.16 to 0.25 mg epinephrine per inhalation not more often than every 3 h. 1 Subsequently, the administrative record was reopened to include the results of a 1983 meeting of the FDA PulmonaryAllergy Drugs Advisory Committee on the issue of OTC marketing of metaproterenol sulfate. 2 Commentary on this issue emphasized that although the nonprescription sale of metaproterenol would have provided a more effective substitute for epinephrine, the latter retains only weak efficacy. This feature reduces the likelihood that OTC epinephrine can effectively mask serious deterioration in pulmonary function, which can occur with more potent inhaled bronchodilators. 3 In the final monograph, published in the Federal Register in 1986, the FDA concluded that there were no additional data to persuade the agency to limit epinephrine inhalation products to prescription use only. 4 Instead, the FDA concluded that with expanded and revised labeling, the continued OTC availability of epinephrine benefits the consumer and is not a safety hazard.
The main elements of this expanded labeling are shown in Table 1 .
Currently, directions for use of these products specify starting with one inhalation, waiting at least 1 min, and then administering one more inhalation if response is inadequate. Patients also are advised not to use the product again for at least 3 h.
This issue was revisited at a joint meeting of the Nonprescription Drugs Committee and the Pulmonary-Allergy Drugs Advisory Committee (both FDA) in 1994, which was convened to reassess the issue of prescription-to-OTC switches of asthma medication, and the safety and effectiveness of OTC asthma treatments. Although split in viewpoints, the group did not recommend removal of OTC epinephrine inhalers, but instead expressed the opinion that labeling should be further strengthened to address inappropriate use. 5 The FDA is currently developing revised labeling intended to better educate users of these products, by adding additional warnings and by revising the sections of the label regarding indication, warnings, and directions. The improved product labeling will emphasize the need for further medical care if symptoms do not improve after using the OTC drug product (Debra Bowen, MD; personal communication; February 1, 1999) .
In 1996, a final rule published in the May 20 Federal Register amended the 1986 final monograph for OTC bronchodilators by removing monograph status for pressurized metered-dose aerosol dosage forms of epinephrine, epinephrine bitartrate, and racepinephrine hydrochloride. 6 Under this rule, OTC sale of such products requires "an approved application containing certain information not required by the monograph." The OTC metereddose inhalers currently on the market were not affected because they already were the subjects of approved new drug applications. This change in monograph status was made to provide a basis "for adequate regulation of the manufacturing of all future OTC metered-dose inhaler aerosol drug products, including those with new propellants," and was not due to "a specific safety or effectiveness concern" about any currently marketed OTC metered-dose inhaler aerosol products.
However, because these products contain chlorofluorocarbons (CFCs), they are subject to provisions of the Clean Air Act Amendments of 1990 and the Montreal Protocol on Substances that Deplete the Ozone Layer, which govern the environmental phaseout of ozone-depleting substances worldwide. 7 Each country that is party to the Montreal Protocol has the responsibility for establishing its standards of phaseout. In March 1997, the FDA published an advanced notice of proposed rule making to establish the standards by which CFC-containing products currently designated as essential would have that status revoked in the United States based on the availability of safe and effective products that do not use CFCs. 8 Metered-dose (oral) inhalers currently fall into the essential use category. 9 The FDA is currently working on the next step in this process, in the form of a Proposed Rule. The time of actual phaseout will depend on the availability of suitable alternatives.
In the event that non-CFC-containing metered-dose (oral) inhalers become available that ensure appropriate patient treatment and safety, CFC-containing inhalers would be phased out as the alternative non-CFC-containing metered-dose inhalers are found acceptable. No distinction has been made in the criteria for how prescription and OTC metered-dose inhalers would be phased out. In the 1997 advanced notice, the FDA reaffirmed that ". . . epinephrine is the only active moiety used in drug products sold over-the-counter (OTC). 8 These OTC drug products are available to patients who may not have access to prescription drugs. Therefore, the FDA has tentatively determined that prescription drug products should not be considered as alternatives to drug products containing epinephrine." Reformulation to non-CFC-containing products would require submission of new or supplemental new drug applications.
Safety and Efficacy of OTC Epinephrine Inhalers
Limited published data are available on the safety and efficacy of OTC epinephrine inhalers. Whitehall-Robins Healthcare presented proprietary data during the 1994 FDA Advisory Committee meeting on two short-term, placebo-controlled, crossover studies in 24 patients and 12 patients, respectively, that showed a significant increase in FEV 1 in the patients using Primatene Mist (Whitehall-Robins Healthcare; Madison, NJ) vs placebo. 5 The pharmacology and metered-dose delivery system for OTC epinephrine theoretically limits its potential for systemic adrenergic side effects under labeled conditions of use, although published dose-response data are unavailable. Because epinephrine activates ␣-adrenoceptors, it causes localized vasoconstriction that would tend to reduce the rate of systemic drug absorption after inhalation. However, chronic abuse of such medication has been reported to cause cardiomyopathy and catecholamine-induced sialadenosis. 10, 11 The latter is characterized by persistent symmetric enlargement of the parotid glands, with infrequent involvement of the submandibular salivary glands. A review of spontaneous adverse reaction reports from 1975 to 1997 found 286 reactions and 13 deaths associated with the use of an epinephrine inhaler. Three of the deaths were believed to be caused by a concomitant medical condition. In the 10 remaining reports, the relationship of epinephrine to the fatal outcome could not be established. Confounding factors were substance abuse, product misuse, and nonrespiratory systemrelated conditions. The manufacturer estimated that Ͼ 115 million Primatene Mist inhalers had been sold in the time frame covered by this review (Barbara Wolf, RPh; personal communication; February 2, 1999). Two deaths associated with abuse of epinephrine inhalers (brand not specified) appeared in poison control data reported from 1994 to 1998. 12, 13 Associations between the use of inhaled ␤-agonists and asthma morbidity and mortality have been reported, especially in the 1960s following the introduction of isoprenaline forte, and in New Zealand in 1976 following the introduction of fenoterol. 14, 15 These agents were supplied in what are now recognized as high-dose formulations and, like epinephrine, they activate ␤ 1 as well as ␤ 2 receptors. To our knowledge, no other ␤-agonists have been implicated in asthma mortality epidemics. However, increasing asthma mortality over the last 2 decades has led some to suggest that the regular use of inhaled ␤-agonists (as a class effect) may be a contributory factor, by increasing asthma severity in some patients. This concept remains unproven, but controversial. 16 -20 In any event, it is not likely to apply to OTC epinephrine inhalers because of their weak potency.
Of greater concern is the possibility that patients with mild-tomoderate persistent asthma may rely on OTC bronchodilators and avoid seeking medical care, which may ultimately lead to disease progression and increased morbidity. Many deaths from asthma are believed to be caused by inadequate or delayed treatment, and therefore are potentially preventable. 21 In countries where a more potent inhaled ␤-agonist (salbutamol) is available OTC, purchase is associated with lower rates of physician consultation, undertreatment of asthma, and less use of prescription asthma medications, especially inhaled corticosteroids. [22] [23] [24] Whether nonprescription availability of OTC epinephrine inhalers in the United States causes patients with mild-to-moderate persistent asthma to self-medicate and delay seeking needed medical care is unknown. Delaying physician consultation would have more to do with the patient's behavior than with the safety and efficacy of OTC inhalers. Some survey data on the use of epinephrine inhalers are available. In a survey involving Ͼ 300,000 households commissioned by Whitehall-Robins Healthcare to determine demographic patterns and use profiles of Primatene Mist, 25, 26 37% of patients with asthma reported using prescription and nonprescription products at different times. About two thirds of this subgroup used the OTC product because their prescription had run out, and one third because a prescription was unavailable. For other demographic features, see Table 2 .
Such surveys are subject to recall bias and, while providing useful population data, do not allow the type of statistical power and detail that would be available by conducting a study of consumers at the time they purchase epinephrine inhalers. Nevertheless, these results suggest that the majority of individuals who report using Primatene Mist represent a population (with mild asthma) and use the drug in accordance with labeled directions; however, approximately 20% also fulfill at least one criterion for asthma severity indicating the presence of mild-tomoderate persistent disease that warrants close physician oversight and treatment with inhaled corticosteroids (nocturnal symptoms Ն 1 week, requirements for urgent care). 27, 28 This interpretation is in agreement with the findings of a smaller analytic study that assessed demographic and clinical covariates of self-treatment with OTC asthma medications. 29 This study recruited participants who exclusively used OTC asthma medications (n ϭ 15), used both prescription and nonprescription asthma medications (n ϭ 13), or used prescription drugs exclusively (n ϭ 22). Except for one subject, all participants who reported using OTC asthma medications were using epinephrine inhalers. Most OTC users were of male gender. Pulmonary function and self-assessed disease severity were similar among groups. However, OTC users' self-assessment of their disease severity was not correlated with the extent to which epinephrine inhalation reversed airflow obstruction. Thus, in this study, OTC bronchodilator users perceived less disability from asthma, but did not differ from prescription users in objective measures of disease severity. Other measures (history of hospitalization, corticosteroid use) indicated that OTC use of epinephrine inhalers was not restricted to persons with only mild, intermittent asthma. A later follow-up study by the same investigators confirmed the relationship between male gender and purchase of OTC epinephrine (or ephedrine) products, but found no association between use of such products and risk of hospitalization due to asthma. 30 
Concerns About the Availability of OTC Epinephrine Inhalers
Because of recent trends toward increased asthma morbidity and mortality, a critical reexamination of current treatment practices and their possible role in adverse short-term and long-term patient outcomes has occurred. This has logically been extended to the OTC arena. Those who oppose the OTC availability of epinephrine inhalers (or any other asthma medication) believe that the availability of asthma medications discourages the implementation of patient education programs, and the use of objective monitoring by limiting contact between patients and qualified medical personnel. The National Heart, Lung, and Blood Institute Asthma Treatment Guidelines stress the need for physician monitoring of asthma patients, the importance of patient education on the use of metered-dose inhalers and peak flow monitors, and the use of the stepped-care approach, which favors earlier use of prescription anti-inflammatory medications. 28 According to this viewpoint, the continuing availability of OTC drugs is a step in the wrong direction, sending the wrong message that asthma is not a serious disease that needs close attention.
Compared with prescription ␤-agonist bronchodilators, epinephrine inhalers are less potent and shorter acting. Conceivably, this should limit the use of the drug by patients with more serious asthma, and also the potential for serious systemic effects, as long as the drug is used according to directions contained in the product labeling. Furthermore, little evidence has been formally presented to indicate that OTC epinephrine metered-dose inhalers are causing any harm to the targeted patient group (ie, those with mild, intermittent disease). Additionally, the availability of at least one OTC asthma quick relief medication allows individuals with mild asthma and those who do not have access to the health-care delivery system to self-medicate.
Conclusion
The occasional use of OTC epinephrine inhalers appears to be safe and effective when used according to labeled instruction by individuals with only mild, intermittent disease. Individuals who grossly misuse or abuse these products are subject to severe adverse reactions, including death. However, limited survey data suggest that approximately 20% of individuals using OTC epinephrine inhalers have mild-to-moderate persistent asthma. According to recent consensus guidelines, these individuals should be under a physician's care and receiving corticosteroid therapy.
Recommendations
The following statements, recommended by the Council on Scientific Affairs, were adopted as American Medical Association (AMA) policy in June 1999.
1. The AMA supports strengthening the product labeling for OTC epinephrine inhalers to better educate users about patterns of inappropriate use; to include clear statements that the use of OTC inhalers can be dangerous; to urge users to seek medical care if symptoms do not improve, or if they meet criteria for the presence of persistent disease; and to encourage explicit discussions with physicians about dosage when these products are used.
2. The AMA encourages the FDA to reexamine whether OTC epinephrine inhalers should be removed from the market.
3. In the event that these products continue to be marketed OTC, further information should be obtained to determine whether OTC availability is a risk factor for asthma morbidity and mortality.
